Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 138,590	$ 104,754	$ 69,056
Cost of product revenue	38,033	22,209	13,742
Research and development	80,099	55,919	44,185
Selling, general and administrative	52,172	49,323	35,049
Restructuring charges	3,167	0	0
Total costs and operating expenses	(173,471)	(127,451)	(92,976)
Income (loss) from operations	(34,881)	(22,697)	(23,920)
Depreciation	(5,402)	(3,113)	(1,950)
Loss before income taxes	(33,316)	(21,090)	(23,671)
Stock-based compensation	14,531	11,593	7,728
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	126,612	90,515	48,106
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	11,978	14,239	20,950
Operating Segments
Segment Reporting Information [Line Items]
Total revenues	138,590	104,754	69,056
Cost of product revenue	38,033	22,209	13,742
Research and development	75,556	53,359	42,628
Selling, general and administrative	17,145	14,860	11,952
Restructuring charges	2,674	0
Total costs and operating expenses	(133,408)	(90,428)	(68,322)
Income (loss) from operations	5,182	14,326	734
Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	126,612	90,515	48,106
Cost of product revenue	38,033	22,209	13,742
Research and development	25,786	23,140	20,923
Selling, general and administrative	14,724	12,105	9,597
Restructuring charges	1,708	0
Total costs and operating expenses	(80,251)	(57,454)	(44,262)
Income (loss) from operations	46,361	33,061	3,844
Stock-based compensation	6,035	5,047	3,296
Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	11,978	14,239	20,950
Cost of product revenue	0	0	0
Research and development	49,770	30,219	21,705
Selling, general and administrative	2,421	2,755	2,355
Restructuring charges	966	0
Total costs and operating expenses	(53,157)	(32,974)	(24,060)
Income (loss) from operations	(41,179)	(18,735)	(3,110)
Stock-based compensation	903	1,100	768
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	33,080	(32,201)	(22,306)
Depreciation	(5,418)	(3,215)	(2,099)
Loss before income taxes	(33,316)	(21,090)	(23,671)
Stock-based compensation	7,593	5,446	3,664
Product revenue
Segment Reporting Information [Line Items]
Total revenues	116,676	70,657	30,220
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	116,676	70,657	30,220
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0
Product revenue | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	116,676	70,657	30,220
Product revenue | Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues		70,657	30,220
Product revenue | Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues		0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	21,914	34,097	38,836
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	9,936	19,858	17,886
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	11,978	14,239	20,950
Research and development revenue | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	$ 21,914	34,097	38,836
Research and development revenue | Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues		19,858	17,886
Research and development revenue | Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues		$ 14,239	$ 20,950